⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CGEN News
Compugen Ltd
Compugen Monetizes Portion of Rilvegostomig Future Royalties to AstraZeneca for Up to $90 Million
prnewswire.com
CGEN
Compugen Reports Third Quarter 2025 Results
prnewswire.com
CGEN
Compugen to Participate in Stifel 2025 Healthcare Conference
prnewswire.com
CGEN
Compugen to Release Third Quarter 2025 Results on Monday, November 10, 2025
prnewswire.com
CGEN
DATROWAY ® Plus Rilvegostomig Showed Promising Tumor Responses in Patients with Metastatic Urothelial Cancer in TROPION-PanTumor03 Phase 2 Trial
businesswire.com
CGEN
Compugen to Present Pooled Analysis of COM701 in Three Phase 1 Trials in Patients with Platinum Resistant Ovarian Cancer at ESMO 2025
prnewswire.com
CGEN
Compugen to Present at SITC 2025
prnewswire.com
CGEN
Q3 Virtual Investor Summit: On-Demand Presentations Now Available
accessnewswire.com
JG
CGEN
COE
GCTK
MRAM
PRSO
UXIN
SPCB
MIND
Compugen to Present Research at the Single Cell Genomics 2025 Conference
prnewswire.com
CGEN